AnaptysBio, Inc.
ANAB Healthcare Biotechnology
AnaptysBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $234.6 million, up 157.0% from fiscal 2024. In the quarter to March 2026, revenue fell 7.98%, EPS fell 43.8% and free cash flow fell 141.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
Follow ANAB
AnaptysBio, Inc. (ANAB) Piotroski F-score
AnaptysBio, Inc.'s Piotroski F-score for fiscal 2025 is 5 out of 9: 5 of nine tests of profitability, leverage and efficiency passed, up from 3 in fiscal 2024.
Piotroski F-score, annual
Embed this chart
Annual newest first
| Period | Piotroski F-score | Change (points) |
|---|---|---|
| FY2025 | 5 | 2.00 |
| FY2024 | 3 | (1.00) |
| FY2023 | 4 | 2.00 |
| FY2022 | 2 | (1.00) |
| FY2021 | 3 | (2.00) |
| FY2020 | 5 | 2.00 |
| FY2019 | 3 | (1.00) |
| FY2018 | 4 | 1.00 |
| FY2017 | 3 | 1.00 |
| FY2016 | 2 | — |
How fiscal 2025’s score is made up
| Test | This year | Year before | Result | Points |
|---|---|---|---|---|
| Positive return on assets | (3.12%) | (31.02%) | Fail | 0 |
| Positive operating cash flow | 19.70m | (135.34m) | Pass | 1 |
| Rising return on assets | (3.12%) | (31.02%) | Pass | 1 |
| Cash flow above net income | 32.93m | 9.89m | Pass | 1 |
| Falling long-term leverage | 0.00 | 0.00 | Pass | 1 |
| Rising current ratio | 9.07 | 9.51 | Fail | 0 |
| No new shares issued | 28,758,000 | 28,382,000 | Fail | 0 |
| Rising gross margin | 100.00% | 100.00% | Fail | 0 |
| Rising asset turnover | 0.55 | 0.19 | Pass | 1 |
| Piotroski F-score | Mixed | 5 | ||
How the Piotroski F-score works
One point for each of nine tests, this fiscal year against the one before: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, a rising current ratio, no new shares issued, a rising gross margin and rising asset turnover. The ratios are the ones on this site, so each can be checked.
Joseph Piotroski (2000) called 8–9 high and 0–1 low; reading it in three bands is the common convention:
| 7–9 | Strong — most fundamentals improved |
|---|---|
| 4–6 | Mixed |
| 0–3 | Weak — most fundamentals deteriorated |
Where this differs from the paper: return on assets is on average rather than beginning-of-year assets, and weighted basic shares stand in for shares issued. The score is shown only when all nine tests can be worked out, which takes three fiscal years; banks and insurers, which report no current assets or gross profit, have none.
Piotroski F-score against peers
| Company | Piotroski F-score |
|---|---|
| RARE Ultragenyx Pharmaceutical Inc. compare | 5 |
| QURE uniQure N.V. compare | 5 |
| ANAB AnaptysBio, Inc. | 5 |
| ABSI Absci Corporation compare | 3 |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | 3 |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | 3 |
| KRSA Korsana Biosciences, Inc. compare | — |
| RAPP Rapport Therapeutics, Inc. compare | — |
| MAZE Maze Therapeutics, Inc. compare | — |
What Piotroski F-score is
The Piotroski F-Score tells an investor how many signs of improving profitability, funding and efficiency a company shows against a year earlier.
One point for each of nine tests against a year earlier: positive return on assets, positive operating cash flow, rising return on assets, cash flow above net income, falling long-term leverage, rising current ratio, no new shares issued, rising gross margin, and rising asset turnover